{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T05:37:30Z","timestamp":1772775450346,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Vifor International"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The iron-based phosphate binders, sucroferric oxyhydroxide (SFOH) and ferric citrate (FC), effectively lower serum phosphorus in clinical studies, but gastrointestinal iron absorption from these agents appears to differ. We compared iron uptake and tissue accumulation during treatment with SFOH or FC using experimental rat models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Iron uptake was evaluated during an 8-h period following oral administration of SFOH, FC, ferrous sulphate (oral iron supplement) or control (methylcellulose vehicle) in rat models of anaemia, iron overload and inflammation. A 13-week study evaluated the effects of SFOH and FC on iron accumulation in different organs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In the pharmacokinetic experiments, there was a minimal increase in serum iron with SFOH versus control during the 8-h post-treatment period in the iron overload and inflammation rat models, whereas a moderate increase was observed in the anaemia model. Significantly greater increases (P\u2009&amp;lt;\u20090.05) in serum iron were observed with FC versus SFOH in the rat models of anaemia and inflammation. In the 13-week iron accumulation study, total liver iron content was significantly higher in rats receiving FC versus SFOH (P\u2009&amp;lt;\u20090.01), whereas liver iron content did not differ between rats in the SFOH and control groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Iron uptake was higher from FC versus SFOH following a single dose in anaemia, iron overload and inflammation rat models and 13\u2009weeks of treatment in normal rats. These observations likely relate to different physicochemical properties of SFOH and FC and suggest distinct mechanisms of iron absorption from these two phosphate binders.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa030","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T20:10:06Z","timestamp":1580933406000},"page":"946-954","source":"Crossref","is-referenced-by-count":4,"title":["Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation"],"prefix":"10.1093","volume":"35","author":[{"given":"J\u00fcrgen","family":"Floege","sequence":"first","affiliation":[{"name":"Division of Nephrology, RWTH University Hospital Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Funk","sequence":"first","affiliation":[{"name":"Department of Medical Affairs, Vifor Pharma, Glattbrugg, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Ketteler","sequence":"first","affiliation":[{"name":"Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjay","family":"Rastogi","sequence":"first","affiliation":[{"name":"Division of Nephrology, University of California, Los Angeles, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Walpen","sequence":"first","affiliation":[{"name":"Department of Medical Affairs, Vifor Pharma, Glattbrugg, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian C","family":"Covic","sequence":"first","affiliation":[{"name":"Nephrology Clinic and Dialysis and Transplantation Center, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart M","family":"Sprague","sequence":"first","affiliation":[{"name":"NorthShore University Health System, University of Chicago, Pritzker School of Medicine, Evanston, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2020061010450201600_gfaa030-B1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"113","year":"2009","journal-title":"Kidney Int"},{"key":"2020061010450201600_gfaa030-B2","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","article-title":"Oral phosphate binders in patients with kidney failure","volume":"362","author":"Tonelli","year":"2010","journal-title":"N Engl J Med"},{"key":"2020061010450201600_gfaa030-B3","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010450201600_gfaa030-B4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"2020061010450201600_gfaa030-B5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","article-title":"Ferric citrate controls phosphorus and delivers iron in patients on dialysis","volume":"26","author":"Lewis","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020061010450201600_gfaa030-B6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.jrn.2014.03.006","article-title":"Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis","volume":"24","author":"Yokoyama","year":"2014","journal-title":"J Ren Nutr"},{"key":"2020061010450201600_gfaa030-B7","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000344008","article-title":"Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Yokoyama","year":"2012","journal-title":"Am J Nephrol"},{"key":"2020061010450201600_gfaa030-B8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40620-014-0108-6","article-title":"Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study","volume":"28","author":"Lee","year":"2015","journal-title":"J Nephrol"},{"key":"2020061010450201600_gfaa030-B9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gft483","article-title":"A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis","volume":"29","author":"Yokoyama","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010450201600_gfaa030-B10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5414\/CNP74004","article-title":"PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease","volume":"74","author":"Geisser","year":"2010","journal-title":"Clin Nephrol"},{"key":"2020061010450201600_gfaa030-B11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2215\/CJN.08230811","article-title":"Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients","volume":"8","author":"Wuthrich","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020061010450201600_gfaa030-B12","first-page":"1330","article-title":"Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide","volume":"32","author":"Covic","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2020061010450201600_gfaa030-B13","first-page":"279","article-title":"Kidney Disease: Improving Global Outcomes Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2020061010450201600_gfaa030-B14","year":"2018"},{"key":"2020061010450201600_gfaa030-B15","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1681\/ASN.2014080842","article-title":"Ferric citrate reduces intravenous iron and erythropoiesis-stimulating agent use in ESRD","volume":"26","author":"Umanath","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2020061010450201600_gfaa030-B16","year":"2019"},{"key":"2020061010450201600_gfaa030-B17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.5527\/wjn.v1.i6.166","article-title":"Hepcidin and HFE protein: iron metabolism as a target for the anemia of chronic kidney disease","volume":"1","author":"Canavesi","year":"2012","journal-title":"World J Nephrol"},{"key":"2020061010450201600_gfaa030-B18","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ajkd.2003.07.016","article-title":"Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences","volume":"42","author":"Kalantar-Zadeh","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2020061010450201600_gfaa030-B19","year":"2008"},{"key":"2020061010450201600_gfaa030-B20","year":"1094"},{"key":"2020061010450201600_gfaa030-B21","year":"2005"},{"key":"2020061010450201600_gfaa030-B22"},{"key":"2020061010450201600_gfaa030-B23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2174\/1389200216666150206124424","article-title":"Preclinical pharmacokinetics, pharmacodynamics and safety of sucroferric oxyhydroxide","volume":"15","author":"Cozzolino","year":"2015","journal-title":"Curr Drug Metab"},{"key":"2020061010450201600_gfaa030-B24","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1074\/jbc.R117.786632","article-title":"Iron transport proteins: gateways of cellular and systemic iron homeostasis","volume":"292","author":"Knutson","year":"2017","journal-title":"J Biol Chem"},{"key":"2020061010450201600_gfaa030-B25","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3390\/nu7042274","article-title":"Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation","volume":"7","author":"Lane","year":"2015","journal-title":"Nutrients"},{"key":"2020061010450201600_gfaa030-B26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cmet.2015.09.006","article-title":"Ironing out ferroportin","volume":"22","author":"Drakesmith","year":"2015","journal-title":"Cell Metab"},{"key":"2020061010450201600_gfaa030-B27","doi-asserted-by":"crossref","first-page":"e1005322","DOI":"10.1371\/journal.pcbi.1005322","article-title":"Modelling systemic iron regulation during dietary iron overload and acute inflammation: role of hepcidin-independent mechanisms","volume":"13","author":"Enculescu","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"2020061010450201600_gfaa030-B28","first-page":"3","article-title":"True iron bioavailability, iron pharmacokinetics and clinically silent side effects","volume":"1","author":"Geisser","year":"2009","journal-title":"Nutr Immun Health"},{"key":"2020061010450201600_gfaa030-B29"},{"key":"2020061010450201600_gfaa030-B30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/ki.1989.290","article-title":"Site and mechanism of enhanced gastrointestinal absorption of aluminum by citrate","volume":"36","author":"Froment","year":"1989","journal-title":"Kidney Int"},{"key":"2020061010450201600_gfaa030-B31","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3390\/ph7100990","article-title":"Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity","volume":"7","author":"Gupta","year":"2014","journal-title":"Pharmaceuticals (Basel)"},{"key":"2020061010450201600_gfaa030-B32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.5414\/CN108119","article-title":"The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro","volume":"81","author":"Wilhelm","year":"2014","journal-title":"Clin Nephrol"},{"key":"2020061010450201600_gfaa030-B33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","article-title":"Systemic iron homeostasis","volume":"93","author":"Ganz","year":"2013","journal-title":"Physiol Rev"},{"key":"2020061010450201600_gfaa030-B34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.4161\/cbt.8.18.9146","article-title":"Abnormal iron uptake and liver cancer","volume":"8","author":"Chen","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"2020061010450201600_gfaa030-B35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.bbagen.2011.07.014","article-title":"Non-transferrin bound iron: a key role in iron overload and iron toxicity","volume":"1820","author":"Brissot","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2020061010450201600_gfaa030-B36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/gut.50.3.413","article-title":"Denatured H-ferritin subunit is a major constituent of haemosiderin in the liver of patients with iron overload","volume":"50","author":"Miyazaki","year":"2002","journal-title":"Gut"},{"key":"2020061010450201600_gfaa030-B37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1055\/s-2005-923314","article-title":"Hepatic iron metabolism","volume":"25","author":"Anderson","year":"2005","journal-title":"Semin Liver Dis"},{"key":"2020061010450201600_gfaa030-B38","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.1021\/ic400484n","article-title":"Ferritin: the protein nanocage and iron biomineral in health and in disease","volume":"52","author":"Theil","year":"2013","journal-title":"Inorg Chem"},{"key":"2020061010450201600_gfaa030-B39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000343856","article-title":"Hepatic iron overload and hepatocellular carcinoma","volume":"3","author":"Kew","year":"2014","journal-title":"Liver Cancer"},{"key":"2020061010450201600_gfaa030-B40","year":"2003"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/6\/946\/33375309\/gfaa030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/35\/6\/946\/33375309\/gfaa030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T15:02:07Z","timestamp":1591801327000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/35\/6\/946\/5817329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa030","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,4,7]]}}}